🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "significant breakthrough" in the battle against increasingly resistant strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

Gonorrhoea infections are on the rise worldwide, with data suggesting over 82 million infections each year. Particularly high rates are observed in Africa and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune advancement in the context of rising global incidence, the spread of superbugs and the very limited treatment choices currently available.”

Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". A tracking program found that the effectiveness of primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Clearance

Zoliflodacin, also known as a brand name, was authorized by the US FDA in mid-December for combating gonorrhoea. This STI can lead to major issues, including infertility. Experts anticipate that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, gained clearance in close succession. This drug, which is employed against UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This authorization signifies a significant shift in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Research Study Results and Global Access

As per findings published in a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This establishes an comparable level with the existing first-line therapy, which involves two antibiotics. The trial involved hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the ability to register and commercialise the drug in numerous developing nations.

Clinicians treating patients have voiced optimism. The availability of a single-dose, oral treatment such as this is described as a "critical tool" for managing the epidemic. This is considered vital to lessen the impact of the illness for patients and to stop the proliferation of untreatable gonorrhoea around the world.